What are the major opportunities in the Vaxneuvance market? What are the strategies for the Vaxneuvance market?

For detailed insights on the major opportunities and strategies in the Vaxneuvance market, Read More

How does the Vaxneuvance market relate to the overall economy and other similar markets?

For detailed insights on Vaxneuvance's relation to the overall economy and other similar markets, Read More

What are the latest mergers and acquisitions in the Vaxneuvance industry?

For detailed insights on the mergers and acquisitions in the Vaxneuvance industry, Read More

What are the key dynamics influencing the Vaxneuvance market growth? SWOT analysis of the Vaxneuvance market.

For detailed insights on the key dynamics influencing the Vaxneuvance market growth and SWOT analysis of the Vaxneuvance industry, Read More

Item added to cart!

Published : December 2025

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Vaxneuvance Global Market Report 2025

Name: Vaxneuvance Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Indication (Pneumonia, Meningitis, Sepsis, Bacteremia, Otitis Media), By Distribution Channel (Pharmacies, Hospitals), By End User (Adults, Children, Geriatric Population)

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Vaxneuvance Market?

Vaxneuvance is a pneumococcal conjugate vaccine designed to protect against invasive diseases caused by specific strains of Streptococcus pneumoniae in adults and children. The vaccine works by stimulating the immune system to recognize and fight 15 serotypes of the bacteria, providing broad protection.

The main indication for vaxneuvance is pneumonia, meningitis, sepsis, bacteremia, and otitis media. Pneumonia is an infection that inflames the air sacs in the lungs, causing symptoms such as cough, fever, and difficulty breathing. Vaxneuvance helps prevent pneumococcal pneumonia by targeting specific serotypes of the streptococcus pneumoniae bacteria. The various distribution channels include pharmacies and hospitals, and several end users including adults, children, and geriatric population.

Vaxneuvance Market Size and growth rate 2025 to 2029: Graph

What Is The Vaxneuvance Market Size 2025 And Growth Rate?

The vaxneuvance market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to rise in incidence of pneumococcal diseases, rise in aging population, rise in supportive regulatory approvals, rise in government funding for vaccination, and increase in travel and globalization.

What Is The Vaxneuvance Market Growth Forecast?

The vaxneuvance market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising chronic conditions, rising antimicrobial resistance, rising respiratory infections in children, increasing cases of immunocompromised populations, and rising healthcare investments. Major trends in the forecast period include development of needle-free vaccine delivery systems, advancements in cold-chain technologies, integration of AI-powered supply chain optimization, integration with digital health records for tracking immunizations, and innovations in adjuvant systems to boost immune response.

Book your 30 minutes free consultation with our research experts

How Is The Vaxneuvance Market Segmented?

The vaxneuvance market covered in this report is segmented –

1) By Indication: Pneumonia; Meningitis; Sepsis; Bacteremia; Otitis Media

2) By Distribution Channel: Pharmacies; Hospitals

3) By End User: Adults; Children; Geriatric Population

What Is Driving The Vaxneuvance Market? Impact Of High Pneumonia Prevalence On Vaccine Demand

The prevalence of pneumonia is expected to drive the growth of the vaxneuvance market going forward. Pneumonia is an infection that causes inflammation in the air sacs of one or both lungs, filling with fluid or pus, resulting in symptoms such as coughing, fever, and breathing difficulties. The prevalence of pneumonia is driven by factors such as viral and bacterial infections, weakened immune systems, air pollution, and the increasing aging population, which makes individuals more susceptible to respiratory infections. Vaxneuvance helps patients by protecting against pneumonia caused by 15 strains of Streptococcus pneumoniae, reducing the risk of severe infections and related complications. For instance, in 2024, according to the Johns Hopkins University, a US-based research university, the mean Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 countries was 56%, an increase of 2% from 54% in 2023. Therefore, the high prevalence of pneumonia is driving the growth of the vaxneuvance market.

What Is Driving The Vaxneuvance Market? Role Of Increasing R&D Investments In Advancing Vaccine Innovation

The growth in research and development investments is expected to drive the vaxneuvance market going forward. Investments in research and development are growing due to increasing demand for innovation and the need to address complex global challenges such as healthcare, sustainability, and digital transformation. The growing investments in research and development support Vaxneuvance by enhancing its vaccine technology and expanding its potential to address evolving healthcare needs. For instance, in July 2024, according to the Department of Health and Social Care, a UK-based government department responsible for the nation's health and social care, in 2022, pharmaceutical research and development in the UK totaled $11.4 billion (£9.0 billion), representing 0.36% of GDP and 18% of all business R&D, the highest among product areas. Therefore, the growth in investments in research and development is driving the growth of the vaxneuvance market.

Who Are The Major Players In The Global Vaxneuvance Market?

Major companies operating in the vaxneuvance market are Merck & Co. Inc.

What Are The Key Trends Of The Global Vaxneuvance Market? Expanding Indications To Enhance Vaccine Accessibility And Impact

The key trend in the vaxneuvance market is vaccine-expanded indications to broaden its target patient population. Expanded indications address unmet medical needs and enhance the vaccine's utility in preventing pneumococcal diseases across diverse age groups. For instance, in June 2022, Merck & Co. Inc., a US-based pharmaceutical company, announced that the United States Food and Drug Administration (FDA) expanded vaxneuvance approval to include children aged 6 weeks to 17 years for preventing invasive pneumococcal disease caused by 15 serotypes. This approval underscores its clinical significance but advises against use in individuals with severe allergies to its ingredients.

Need data on a specific region in this market?

Request Regional Data

Regional Analysis For The Global Vaxneuvance Market

North America was the largest region in the vaxneuvance market in 2024. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vaxneuvance market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Vaxneuvance Market?

The vaxneuvance market consists of sales of pneumococcal 15-valent conjugate vaccines, adjuvants, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Vaxneuvance Industry?

The vaxneuvance market research report is one of a series of new reports from The Business Research Company that provides vaxneuvance market statistics, including the vaxneuvance industry's global market size, regional shares, competitors with a vaxneuvance market share, detailed vaxneuvance market segments, market trends and opportunities, and any further data you may need to thrive in the vaxneuvance industry. This vaxneuvance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Author : Abhilash Pyata

Vaxneuvance Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	Included ?
Revenue Forecast In 2034	Included ?
Growth Rate	Included ?
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The vaxneuvance market covered in this report is segmented – 1) By Indication: Pneumonia; Meningitis; Sepsis; Bacteremia; Otitis Media 2) By Distribution Channel: Pharmacies; Hospitals 3) By End User: Adults; Children; Geriatric Population
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Merck & Co. Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Vaxneuvance Market Characteristics

3. Vaxneuvance Market Biologic Drug Characteristics

3.1. Molecule Type

3.2. Route Of Administration (ROA)

3.3. Mechanism Of Action (MOA)

3.4. Safety And Efficacy

4. Vaxneuvance Market Trends And Strategies

5. Vaxneuvance Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

6. Global Vaxneuvance Growth Analysis And Strategic Analysis Framework

6.1. Global Vaxneuvance PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

6.2. Analysis Of End Use Industries

6.3. Global Vaxneuvance Market Growth Rate Analysis

6.4. Global Vaxneuvance Historic Market Size and Growth, 2019 - 2024, Value ($ Million)

6.5. Global Vaxneuvance Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)

6.6. Global Vaxneuvance Total Addressable Market (TAM)

7. Global Vaxneuvance Pricing Analysis & Forecasts

8. Vaxneuvance Market Segmentation

8.1. Global Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Pneumonia

Meningitis

Sepsis

Bacteremia

Otitis Media

8.2. Global Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Pharmacies

Hospitals

8.3. Global Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Adults

Children

Geriatric Population

9. Global Vaxneuvance Epidemiology Of Clinical Indications

9.1. Drug Side Effects

9.2. Incidence And Prevalence of Clinical Indications

10. Vaxneuvance Market Regional And Country Analysis

10.1. Global Vaxneuvance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

10.2. Global Vaxneuvance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11. Asia-Pacific Vaxneuvance Market

11.1. Asia-Pacific Vaxneuvance Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11.3. Asia-Pacific Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11.4. Asia-Pacific Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

12. China Vaxneuvance Market

12.1. China Vaxneuvance Market Overview

12.2. China Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

12.3. China Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

12.4. China Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

13. India Vaxneuvance Market

13.1. India Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

13.2. India Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

13.3. India Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14. Japan Vaxneuvance Market

14.1. Japan Vaxneuvance Market Overview

14.2. Japan Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14.3. Japan Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14.4. Japan Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15. Australia Vaxneuvance Market

15.1. Australia Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15.2. Australia Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15.3. Australia Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16. South Korea Vaxneuvance Market

16.1. South Korea Vaxneuvance Market Overview

16.2. South Korea Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16.3. South Korea Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16.4. South Korea Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17. Western Europe Vaxneuvance Market

17.1. Western Europe Vaxneuvance Market Overview

17.2. Western Europe Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17.3. Western Europe Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17.4. Western Europe Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18. UK Vaxneuvance Market

18.1. UK Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18.2. UK Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18.3. UK Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19. Germany Vaxneuvance Market

19.1. Germany Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19.2. Germany Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19.3. Germany Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20. France Vaxneuvance Market

20.1. France Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20.2. France Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20.3. France Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21. Eastern Europe Vaxneuvance Market

21.1. Eastern Europe Vaxneuvance Market Overview

21.2. Eastern Europe Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21.3. Eastern Europe Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21.4. Eastern Europe Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22. North America Vaxneuvance Market

22.1. North America Vaxneuvance Market Overview

22.2. North America Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22.3. North America Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22.4. North America Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23. USA Vaxneuvance Market

23.1. USA Vaxneuvance Market Overview

23.2. USA Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23.3. USA Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23.4. USA Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24. Canada Vaxneuvance Market

24.1. Canada Vaxneuvance Market Overview

24.2. Canada Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24.3. Canada Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24.4. Canada Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25. South America Vaxneuvance Market

25.1. South America Vaxneuvance Market Overview

25.2. South America Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25.3. South America Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25.4. South America Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26. Middle East Vaxneuvance Market

26.1. Middle East Vaxneuvance Market Overview

26.2. Middle East Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26.3. Middle East Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26.4. Middle East Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27. Africa Vaxneuvance Market

27.1. Africa Vaxneuvance Market Overview

27.2. Africa Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27.3. Africa Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27.4. Africa Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

28. Vaxneuvance Market Competitive Landscape And Company Profiles

28.1. Vaxneuvance Market Competitive Landscape

28.2. Vaxneuvance Market Company Profiles

28.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Vaxneuvance Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Vaxneuvance Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Vaxneuvance Market

32. Recent Developments In The Vaxneuvance Market

33. Vaxneuvance Market High Potential Countries, Segments and Strategies

33.1 Vaxneuvance Market In 2029 - Countries Offering Most New Opportunities

33.2 Vaxneuvance Market In 2029 - Segments Offering Most New Opportunities

33.3 Vaxneuvance Market In 2029 - Growth Strategies

33.3.1 Market Trend Based Strategies

33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations

34.2. Currencies

34.3. Historic And Forecast Inflation Rates

34.4. Research Inquiries

34.5. The Business Research Company

34.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Million

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million

Table 3: Global Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 4: Global Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 5: Global Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 6: Global Vaxneuvance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 7: Global Vaxneuvance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 8: Asia-Pacific, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 9: Asia-Pacific, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 10: Asia-Pacific, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 11: China, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 12: China, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 13: China, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 14: India, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 15: India, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 16: India, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 17: Japan, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 18: Japan, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 19: Japan, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 20: Australia, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 21: Australia, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 22: Australia, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 23: South Korea, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 24: South Korea, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 25: South Korea, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 26: Western Europe, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 27: Western Europe, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 28: Western Europe, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 29: UK, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 30: UK, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 31: UK, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 32: Germany, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 33: Germany, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 34: Germany, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 35: France, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 36: France, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 37: France, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 38: Eastern Europe, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 39: Eastern Europe, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 40: Eastern Europe, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 41: North America, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 42: North America, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 43: North America, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 44: USA, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 45: USA, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 46: USA, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 47: Canada, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 48: Canada, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 49: Canada, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 50: South America, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 51: South America, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 52: South America, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 53: Middle East, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 54: Middle East, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 55: Middle East, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 56: Africa, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 57: Africa, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 58: Africa, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Table 59: Merck & Co. Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Million

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Million

Figure 3: Global Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 4: Global Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 5: Global Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 6: Global Vaxneuvance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 7: Global Vaxneuvance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 8: Asia-Pacific, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 9: Asia-Pacific, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 10: Asia-Pacific, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 11: China, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 12: China, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 13: China, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 14: India, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 15: India, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 16: India, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 17: Japan, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 18: Japan, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 19: Japan, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 20: Australia, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 21: Australia, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 22: Australia, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 23: South Korea, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 24: South Korea, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 25: South Korea, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 26: Western Europe, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 27: Western Europe, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 28: Western Europe, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 29: UK, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 30: UK, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 31: UK, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 32: Germany, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 33: Germany, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 34: Germany, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 35: France, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 36: France, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 37: France, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 38: Eastern Europe, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 39: Eastern Europe, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 40: Eastern Europe, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 41: North America, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 42: North America, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 43: North America, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 44: USA, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 45: USA, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 46: USA, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 47: Canada, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 48: Canada, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 49: Canada, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 50: South America, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 51: South America, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 52: South America, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 53: Middle East, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 54: Middle East, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 55: Middle East, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 56: Africa, Vaxneuvance Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 57: Africa, Vaxneuvance Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 58: Africa, Vaxneuvance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

Figure 59: Merck & Co. Inc. Financial Performance

2025 Over-The-Counter (OTC) Diet Products Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Parathyroid Disease Treatment Market Revenue Outlook: Strategic Insights and Forecast to 2029

Industry Forecast: PCSK9 Inhibitor Market to Generate $6.87 Billion Revenue by 2029

CAGR of 5.4% Projected for Pediatric Asthma Treatment Market From 2025 to 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the MSI-H and DMMR Market with 2025 insights from The Business Research Company.

Pediatric Vaccine Market 2025 – By Vaccine Type (Monovalent Vaccines, Multivalent Vaccines), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Conjugate Vaccines, Other Technologies), By App...

Vaccines Market 2023 – By Type (Anti-Infective Vaccines, Anti-Cancer Vaccines, Other Type), By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vacc...

H1N1 Vaccine Global Market Report 2025 – By Product Type( Inactivated Vaccine, Live Attenuated Vaccine ), By Route Of Administration( Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination ), By End...

Pediatric Vaccine Global Market Report 2025 – By Vaccine Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Toxoid, Conjugate, Other Technologies), By Application (Infectious Disease, Allergy, C...

Companion Animal Veterinary Vaccines Global Market Report 2025 – By Product (Inactivated, Live Attenuated, Recombinant, Other Products), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By D...

Cancer Vaccines Global Market Report 2025 – By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), By Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vac...

DTP Vaccines Global Market Report 2025 – By Product type (DTaP, TD, Tdap), By Disease (Diphtheria, Pertussis, Tetanus), By End-User (Hospitals, Clinics, Vaccination Centers) – Market Size, Trends, And Global Forecast 202...

Frequently Asked Questions

What is the definition of the Vaxneuvance market?

How will the Vaxneuvance market drivers and restraints affect the market dynamics? What forces will shape the Vaxneuvance industry going forward?

The Vaxneuvance market major growth driver - Impact Of High Pneumonia Prevalence On Vaccine Demand. For further insights on the Vaxneuvance market, request a sample here

What is the forecast market size or the forecast market value of the Vaxneuvance market?

The Vaxneuvance market size has grown strongly in recent years. The vaxneuvance market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to rise in incidence of pneumococcal diseases, rise in aging population, rise in supportive regulatory approvals, rise in government funding for vaccination, and increase in travel and globalization. The vaxneuvance market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising chronic conditions, rising antimicrobial resistance, rising respiratory infections in children, increasing cases of immunocompromised populations, and rising healthcare investments. Major trends in the forecast period include development of needle-free vaccine delivery systems, advancements in cold-chain technologies, integration of AI-powered supply chain optimization, integration with digital health records for tracking immunizations, and innovations in adjuvant systems to boost immune response. For further insights on the Vaxneuvance market, request a sample here

How is the Vaxneuvance market segmented?

The vaxneuvance market covered in this report is segmented –
1) By Indication: Pneumonia; Meningitis; Sepsis; Bacteremia; Otitis Media
2) By Distribution Channel: Pharmacies; Hospitals
3) By End User: Adults; Children; Geriatric Population For further insights on the Vaxneuvance market, request a sample here

Which region has the largest share of the Vaxneuvance market? What are the other regions covered in the report?

Who are the major players in the Vaxneuvance market?

Major companies operating in the vaxneuvance market are Merck & Co. Inc. . For further insights on the Vaxneuvance market, request a sample here.

What are the key trends in the Vaxneuvance market?

Major trends in the Vaxneuvance market include Expanding Indications To Enhance Vaccine Accessibility And Impact. For further insights on the Vaxneuvance market, request a sample here.